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Controlled trials to assess the therapeutic benefit of 
orthotopic hepatic transplantation (OHrx) for pri-
mary sclerosing cholangitis (PSC) cannot be justified 
in view of improvement of patient survival after this 
operation since 1981. However, the actual patient sur-
vival with OHTx can be compared with the Mayo 
model estimated survival probabilities without OHrx. 
This model, which encompasses physical, biochemical 
and histopathologic parameters of PSC, was constructed 
from a study of 392 conservatively treated PSC pa-
tients at five international centers in England and 
North America. 
We compared the actual survival of 216 adult pa-
tients with the diagnosis of advanced PSC who un-
derwent hepatic replacement with the expected sur-
vival estimated by the Mayo PSC natural history model, 
"the simulated control technique." OHrx was per-
formed at the University of Pittsburgh and Mayo Medi-
cal Center between 5 December 1981 and 26 Decem-
ber 1990. The mean (plus or minus standard deviation) 
post-OHTx follow-up period was 34±25 months 
(range of zero to 104 months). Before transplantation, 
biliary or portal hypertensive operation, or both, was 
performed upon 104 patients. At operation, the mean 
age of recipients was 42.1 ± 11.3 years and the mean 
value of total serum bilirubin was 13.3 ± 13.0 milli-
grams per deciliter. Extensive septal fibrosis and cir-
rhosis were histologically documented in 97 percent 
of the patients, with splenomegaly in 63 percent. Im-
munosuppressive therapy was based primarily on cy-
closporin in 184 recipients and FK-506 in 32. 
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Within six months, the Kaplan-Meier survival prob-
ability after OHrx (0.89) already was higher than 
predicted by the Mayo model (0.83). At five years, 
the Kaplan-Meier actual survival with OHrx was 0.73 
compared with 0.28 expected Mayo model survival. 
The overall increased survival rate with transplantation 
was statistically significant (chi-square equals 126.6; 
p<O.OOI). At all risk stratifications, OHrx significantly 
improved survival with a p value of 0.031 (low risk), 
0.001 (moderate risk) and <0.001 (high risk). Thus, 
OHrx is effective therapy for PSc. Disease gravity 
and unsuspected cholangiocarcinoma in the excised 
native liver adversely influenced short and long term 
survival rates after transplantation, respectively. Surg. 
Gynecol. Obstet., 1993, 177: 335-344. 
HEPATIC TRANSPLA:-..iTU\ON has evolved during the last 
decade to be the most effective and definitive 
therapeutic modality for patients with end stage 
hepatic diseases, including primary sclerosing cho-
langitis (PSC) (1-3). Obviously, random assign-
ment of these patients to a conservative treatment 
"control group" is considered to be ethically and 
clinically inappropriate. ' 
At the Mayo Medical Center, a simulated con-
trol technique "natural history model" for pre-
dicting the probability of survival in conservatively 
treated patients with PSC has been made (4) 
and recently refined (5). A similar model, but 
with different risk variables, was designed for pri-
mary biliary cirrhosis (6), which was used in a 
recent study (7) to assess the efficacy of ortho-
topic hepatic transplantation (OHTx) in these 
patients. 
To provide control data for evaluating the ef-
ficacy of OHTx in improving survival for patients 
with advanced PSC, the Mayo PSC natural history 
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FIG. 1. AClual (Kaplan-Meier) survival after transplantation 
in 216 patients with primarv sclerosing cholangitis and their 
estimated survival without transplantation as predicted by 
the Mayo model "simulated control." 
model was mathematically applied to the com-
bined population of patients with PSC who un-
derwent hepatic replacement at the University 
of Pittsburgh and Mayo Medical Center. Actual 
survival after transplantation was compared with 
the survival estimated with the use of the Mayo 
model. These data were carefully analyzed to es-
timate the survival advantage of OHTx in this 
unique population. 
MATERIALS AND METHODS 
Mayo PSC natural history model. The control group 
used in the current evaluation of the effect of 
OHTx on patient survival was formed according 
TABLE I.-VALliES FOR MAYO MODEL VARIABLES IN PA-
TIENTS WITH PRIMARY SCLEROSING CHOLANGITIS 
TREATED wIn! AND WIT! lOUT HEPATIC TRANSPLANTA-
TIOl\l 
Variable 
Age. yrs. 
Mean±S.D. 
Range 
Bilirubin, mgm./ d1. 
Mean±S.D ............ . 
Range .... . 
Splenomegaly .......... . 
Histologic stage* . . . . . . . . . . 
1 and 2 
3 .. 
4 ........ 
Risk score l 
Mean ±S.D .... 
Range .. 
"Mean ±S.D. 
tAccording to the Mayo model. 
N(/tural history 
groUI), n=392 
41.3±l3.9 
17 to RO 
4.3±6.3 
0.2 to 36 
120 (30.6) 
2.7±1.l 
160 (40.S) 
116 (29.6) 
116 (29.6) 
3.3±1.3 
0.6 to 6.S 
NWllbers ill parclltheses are percentages. 
Transplanted 
group, n=216 
42.1±11.3 
IS to 69 
13.3±l3.0 
0.2 to S3 
137 (G3.4) 
3.S±O.3 
7 (3.2) 
33 (15.3) 
176 (SL5) 
5.0±0.9 
1.7 to 6.R 
to data generated by the Mayo model for assessing 
survival in relation with the natural history of 
PSC (5). This is a Cox proportional hazards re-
gression model (8, 9) that uses a small number 
of variables to predict survival in patients who 
are conservatively treated. The model was made 
from a combined data set consisted of 426 pa-
tients with PSC who had been referred to five 
international medical centers (three in the United 
States and two in the United Kingdom), between 
July 1973 and September 1989. The final model, 
however, was fit only to 392 patients who had 
complete data for all of the variables included 
in the model (5). All of the patients met the 
standard clinical, biochemical, radiologic and his-
tologic criteria for the diagnosis ofPSC (10-12). 
Patients were excluded from the study if they 
were less than 16 years of age or had histologically 
proved concomitant cholangiocarcinoma at the 
time of referral. Patients with attempts of surgical 
or roentgenologic decompression, or both, of the 
biliary tract were not excluded because these in-
terventions are not thought to alter survival mean-
ingfully. Of the :392 patients, 49 received a hepatic 
transplant after the initial referral and the fol-
low-up evaluation of these patients was censored 
at transplantation. It is important to note that 
24 patients of this group were found to have 
unsuspected cholangiocarcinoma by examining 
the hepatectomy specimen after transplantation 
or at autopsy. 
The Mayo PSC model uses the age of the pa-
tient and three other different variables that meas-
ure disease severitv-total serum bilirubin, 
splenomegaly and hi~tologic stage on hepatic bi-
opsy. These variables were measured for all pa-
tients at time of referral. The model combines 
these four prognostic variables to obtain a risk 
score (R) for each patient using the equation: 
R=0.041 (age in years) + 0.5:35 loge (bilirubin 
in milligrams per deciliter) + 0.705 (splenomegaly 
score) + 0.486 (histologic score). Splenomegaly 
was defined based upon clinical or roentgenologic, 
or both, data and the score was given zero for 
absence and one for presence of splenic enlarge-
ment. Histologic stage was determined according 
to the pathologic changes seen on hepatic bi-
opsies. All hepatic specimens taken at biopsy were 
restaged according to the Ludwig criteria (13). 
The results of statistical analysis suggest that a 
particularly useful score of histologic stage con-
sists of using the value 1 for stage 1 and 2, the 
valve 2 for stage 3 and the value 4 for stage 4 
(4, 5). The value of the individual prognostic 
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FIG. 2. Actual (Kaplan-Meier) survival after transplantation in three risk groups 
of patients with primary sclerosing cholangitis and the estimated survival without 
transplantation as predicted by the Mayo natural history model. These risk groups 
were formed on the basis of pre transplantation Mayo-model risk scores with a 
cutoff value of 4.8 for the low risk and 5.4 for the moderate risk group. 
variables for patients that were used to build 
and validate the model, as well as the calculated 
risk score, are given in Table I. 
The R is then used to generate a predicted 
survival probability curve for each patient based 
upon the risk level. This curve shows the prob-
ability that the individual will live a given number 
of years after the risk variables have been meas-
ured. Technical details are available elsewhere 
(5). The model was internally cross validated by 
using data splitting (14) and intramural tech-
niques. The 95 percent confidence intervals for 
the estimated survival probability measured by 
the jackknife procedure (15, 16) showed accept-
able accuracy for most of the patients who were 
individually studied among the total population, 
as well as the risk groups (5). 
Patient population. Between December 1981 and 
December 1990, 1,785 patients underwent pri-
mary OHTx at the University of Pittsburgh Medi-
cal Center. At Mayo Medical Center, another 236 
patients received OHTx during the period from 
March 1985 to December 1990. Cyclosporin and 
steroids were the baseline immunosuppressive treat-
ment for all patients until the introduction of 
the new immunosuppressive agent FK-506 in March 
of 1989 (17). Beginning in November 1984, OKT3 
was used to treat some episodes of allograft re-
jection. 
Before transplantation, the diagnosis of the un-
derlying hepatic disease was established in each 
patient on the basis of thorough clinical, bio-
chemical, roentgenologic and histologic assess-
ments in addition to other metabolic and im-
munologic tests. The diagnosis of PSC was given 
to 173 of the patients at the Pittsburgh facility 
and 58 of the patients at the Mayo Clinic. The 
diagnosis was confirmed in all patients by serial 
histologic examination of the hepatectomy speci-
men. Based upon the selection criteria adopted 
TABLE n.-VALUES FOR MAYO MODEL VARIABLES IN 216 
PRIMARY SCLEROSING CHOLANGITIS LIVER RECIPIENTS 
STRATIFIED ACCORDING TO THE CENTER OF TRANSPLAN-
TATION 
Variable 
Age, yrs.* ..... . 
Bilirubin, mgm./dl.* 
Splenomegaly . . . . 
Histologic stage* . . 
1 and 2 ..... . 
3 ......... . 
4 ......... . 
Risk score* .... . 
*Mean±S.D. 
University of Pitts-
burgh, n=158 
41.6±l1.7 
14.1±13.4 
116 (73.4) 
3.7±0.6 
7 (4.4) 
30 (19) 
121 (76.6) 
5.1±0.9 
Numbers in parentheses are percentages. 
Mayo Medical 
Center, n=58 
43.5±10.0 
1 1.2±1 1.5 
21 (36.2) 
3.9 ±O.2 
o (0) 
3 (5.2) 
55 (94.8) 
4.9±0.9 
p Value 
0.2 
0.06 
<0.001 
0.002 
0.2 
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FIG. C). Kaplan-Meier actual survival after transplantation in patients with primarY sclerosing 
cholangitis with and without inflammatory intestinal disease. The actual survival rate at five year 
is 0.70 ± 0.09 and 0.88 ± 0.05 for each subgroup, respectively. 
FIG. 4. Anual (Kaplan-Meier) survival after transplantation in patients with primary sclerosing 
cholangitis with and without a history of biliary and portal hypertensivf' operation before trans-
plantation. The actual survival rate at five veal' is 0.67 ± 0.06 and 0.7R -± 0.05 for each subgroup, 
respectively. 
to build the Mayo PSC natural history model, 
15 of these combined 231 patients were excluded. 
Seven patients had the pretransplant diagnosis 
of concomitant cholangiocarcinoma and four were 
less than 16 years of age. The remaining four 
patients had concomitant pathologic lesions that 
could influence patient survival, namely Hodgkin's 
lymphoma, eosinophilic granuloma, Al antitryp-
sin deficiency and multiorgan polycystic disease. 
Of the 216 patients included in the study, 141 
were male and 75 were female. A history of in-
flammatory intestinal disease was documented in 
174 patients and total colectomy was required 
in 29 because of either active intestinal disease 
or complicating carcinoma. Biliary or portal hy-
pertensive, or both, surgical treatment was per-
formed before transplantation in 104 patients. 
Attempts of surgical or roentgenologic, or both, 
biliary drainage were reported in 73 patients. 
The primary indications for OHTx in most patients 
were poor hepatic function or large esophageal 
varices, witb repeated massive upper gastroin-
testinal hemorrhage, or both. Unsuspected cho-
langiocarcinoma was detected in the hepatectomy 
specimen in 11 patients. All patients received trans-
plantation between 5 December 1981 and 26 De-
cember 1990 (median transplant date was mid-
January 1988). The primary immunosuppressive 
agent was cyclosporin in 184 patients and FK-506 
in 32. During the study period, 30 of the patients 
receiving cyclosporin were changed to FK-506 and 
one of the FK-506 group was changed to cy-
closporin. 
The descriptive statistics for the 216 hepatic 
recipients are given in Table I. The four prog-
nostic variables used were measured at the time 
of transplantation and obtained from the medical 
records of the patients. The criteria used to meas-
ure these variables were essentially the same ones 
used for the natural history "Mayo model" group. 
Almost all the histologic slides obtained from 
the hepatectomy specimen were reviewed and 
restaged by the same pathologic team, adopting 
the same histologic criteria (13). Values for the 
individual risk factors among the patients at the 
Pittsburgh facility and Mayo Clinic are listed in 
Table II. Follow-up evaluation was complete for 
all patients as of 30 June 1991. 
Statistical analysis. The comparison between the 
Pittsburgh group and patients receiving transplants 
at Mayo was done using the rank sum tests for 
continuous and the chi-square test for categorical 
prognostic variables. Survival time was defined 
as the time that elapsed from the initial OHTx 
until death or the date of last follow-up evalu-
ation. All patients were included in the analysis, 
including those who required multiple transplants. 
Thirty-seven patients had undergone transplan-
tation twice, seven received three grafts, two re-
ceived four grafts and one patient received six 
grafts. When analyzing the effect of the immu-
nosuppressive regimen on patient survival, we cen-
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FIG. 5. Kaplan-Meier survival plot after transplantation in patients with primary sclerosing cho-
langitis with and without detection of cholangiocarcinoma in the excised liver. The difference 
was statistically significant, with a five-year survival rate of 0.47 ± 0.17 and 0.75 ± 0.04, respectively. 
FIG. 6. Actual (Kaplan-Meier) survival after transplantation in patients with primary sclerosing 
cholangitis who had incidental cholangiocarcinoma and the estimated (Mayo Model) survival 
rate without transplantation. The three year survival rate is 0.47 ± 0.17 and 0.31, respectively. 
sored patients at the time of their change from 
one agent to the other. 
The actual post-transplantation survival rate was 
estimated by the Kaplan-Meier product limit es-
timator (18). The predicted survival rate without 
transplantation was computed for each patient 
using the Mayo natural history model, along with 
the values of the four prognostic variables at 
the time of transplantation. The values for actual 
and model predicted survival rates were com-
pared graphically and by means of a statistical 
test. 
For the graphic method, the individual prob-
abilities for predicted survival rate were averaged 
to produce a mean Mayo model survival curve 
to be compared with the Kaplan-Meier survival 
curve. For purposes of presentation, the averaged 
Mayo model survival probabilities were computed 
at only a few times after transplantation (three 
months, six months and at yearly intervals) and 
then interpolated linearly. 
The difference between the survival predicted 
with the Mayo model and the actual survival was 
tested using the one sample log rank test (19). 
This test uses the Mayo model predicted survival 
curve for each patient as a mathematical control 
for that patient. 
To assess the efficacy of OHTx for patients 
with different levels of disease severity, the 216 
patients receiving OHTx were classified into three 
risk groups based upon the Mayo model risk 
score. The risk score cutoff values dividing the 
groups (4.8 and 5.4) were selected so that the 
three groups had roughly equal numbers of total 
deaths after transplantation. The low-risk group 
had 78 patients, with 15 deaths; the moderate 
risk group had 53 patients, with 15 deaths and 
the high-risk group had 85 patients, with 17 deaths. 
Within each risk group, the actual and predicted 
survival were compared using the one sample 
log rank test. The relation between the Mayo 
model risk score and the actual post-transplan-
tation survival rate was assessed using the Cox 
proportional hazards regression procedure. As in 
the study of efficacy of OHTx for primary biliary 
cirrhosis (7), two analyses were used. One analysis 
examined the entire follow-up period and the 
other was restricted to the first three months 
after transplantation. 
TABLE IlL-VALUES FOR MAYO MODEL VARIABLES IN 216 
PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS 
CLASSIFIED IN RISK SUBGROUPS 
Variable 
Age, yrs.* ...... . 
Bilirubin, mgm./ dl. * . 
Splenomegaly . . . . . 
Histologic stage* . . . 
1 and 2 ...... . 
3 .......... . 
4 .......... . 
Risk score* ..... . 
*Mean ±S.D. 
Low, n=78 
36.3±9.8 
6.2±5.4 
29 (37.2) 
3.6±0.7 
5 (6.4) 
21 (26.9) 
52 (66.7) 
4.1±0.6 
Numbers in parentheses are percentages. 
Moderate, n=53 
43.0±12 
12.7±l3.9 
35 (66) 
3.7±O.6 
2 (3.8) 
10 (18.9) 
41 (77.3) 
5.1±O.2 
High, n=85 
46.8±9.7 
20.2±13.8 
73 (85.9) 
4.0±0.2 
o (0) 
2 (2.4) 
83 (97.6) 
5.9±0.4 
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FIG. 7. Actual (Kaplan-Meier) survival after transplantation 
in patients with primary sclerosing cholangitis subclassified 
according to the used iIlllTlunosuppressive regimen. 
Because of the coexistence of other potential 
risk factors that were not included in the YIavo 
model, patients were subclassified according to 
the presence of inflammatory intestinal disease, 
history of pre transplant biliary or portal hyper-
tensive, surgical treatment and detection of cho-
langiocarcinoma in the hepatectomy specimen. 
The effect of each of these risk factors on the 
actual survival rate was tested using log rank test 
(20). Cox regression, with the risk score as a 
covariate, was used to balance statistically the dis-
ease severi ty in these subgroups (8). 
The influence of the available immunosuppres-
sive agents on post-transplantation outcome was 
assessed by subclassifying the total population into 
three subgroups-patients who underwent trans-
plantation bef(we OKT3 was available (November 
1984) and treated with cyclosporin, patients who 
underwent transplantation after OKT3 was used 
to treat severe rejection and received cyclosporin 
as the primary immunosuppressive agent and pa-
tients who were primarily treated from the outset 
with FK-506. The log rank test and Cox regression 
procedure were used to compare survival rates 
in these three groups. The differences in disease 
severity at baseline were controlled for by in-
cluding the risk score from the Mayo model as 
a covariate. 
Survival calculations and log rank tests were 
done by using the SAS procedure SURVDIFF 
and Cox regressions were calculated by using 
the SAS procedure PHGLM (21). For all of the 
statistical analyses used, two-tailed p values were 
reported. 
RESULTS 
Patients with PSC receiving OHTx at the Pitts-
burgh facility and Mayo Clinic were combined 
based upon a comparable risk score (p=0.159) 
and a similar actual (Kaplan-Meier) slUyival (p= 
0.3(5). The entire study population had more 
advanced disease than the patients used to build 
the natural history model (Table I). The mean 
value of serum bilirubin, incidence of splenome-
galy and histologic stage of hepatic disease were 
substantially higher in the patients receiving trans-
plantation at the time of operation compared 
with the natural history group at the time of 
referral. Consequently, the patients receiving 
transplantation had higher risk scores, with a 
mean value of 5.0 ± 0.9 compared with 3.3 ± 1.3 
for the Mayo model data set group. However, 
because the range of the risk scores is similar 
in both groups, we are not extrapolating beyond 
the range of the model when we predict the 
survival of the patients receiving transplantation. 
With a mean follow-up period of 34 ± 25 months 
(range of zero to 104 months), 47 patients died 
after OHTx. Nineteen of these deaths occurred 
during the first three months postoperatively with 
fulminant sepsis or graft failure, or both, being 
the main causes of death. The actual post-trans-
plantation Kaplan-Meier survival rate for the 216 
patients with PSC and the averaged Mayo model 
expected survival rate are depicted in Figure 1. 
The two curves were very similar during the first 
three months after transplantation, a period dur-
ing which the observed post-transplantation sur-
vival probability decreased sharply. The curves 
diverged later during the postoperative course. 
At six months after transplantation, the mean 
actual survival probability was 0.89 ± 0.02 and the 
average Mayo model survival probability was 0.83. 
At one year, these estimates were 0.86 ± 0.02 and 
0.70, respectively. At five years, the difference 
substantially increased with a value of 0.73 ± 0.04 
for actual survival and 0.28 for expected survival. 
The one sample log rank test showed the dif· 
ference between the overall actual survival after 
transplantation and the expected survival e~timated 
bv the Mayo model to have a high level of sig-
nificance (chi-square equals 126.6; p<O.OOl). 
The values of the individual risk factors for 
each of the three risk groups are listed in Table 
Ill. The actual (Kaplan-Meier) survival rate and 
the average survival rate based on the Mayo model 
for each of the risk groups are illustrated in 
Figure 2. At each risk level, the actual survival 
rate after transplantation was significantly better 
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than the survival rate predicted by the Mayo model, 
with a p value of 0.031 for the low, MK~M1 ~or 
the moderate and less than 0.00l for the hlgh-nsk 
group. .. 
Even patients at. low nsk, with better chance 
of survival with no treatment according to Mayo 
model, still had better post-transplantation sur-
vival (Fig. 2). The actual survival rate after trans-
plantation, however, was not significantly different 
among the three risk groups (chi-square equals 
2.7; p=0.259). A Cox analysis assessing the asso-
ciation of the risk score with the overall actual 
survival rate for each patien t indicated that the 
Mayo model risk score was not a significant pre-
dict.or of survival after transplantation (chi-square 
equals 1.6; p=0.202). However, when the analysis 
was restricted to the first 90 days after trans-
plantation, the Mayo model risk score became 
a significant predictor of actual survival (chi-square 
equals 6.0; p=0.(14). 
The possible effect of the potential risk factors 
that are not included in the Mayo model on 
patient survival was also examined in this study. 
Patients with concomitant inflammatory intestinal 
disease or who underwent biliary or portal hy-
pertensive, or both, operation, tended to have 
a less favorable survival after OHTx (Figs. 3 and 
4, respectively). However, these reductions in the 
actual survival rate were not statistically significant 
(for inflammatory intestinal disease, p=0.1l7; for 
biliary and portal hypertensive operation, p=0.148). 
These findings remained nonsignificant even af-
ter adjustment for the risk scores. 
The difference in the long term actual survival 
rate after transplantation between patients who 
had cholangiocarcinoma in the excised liver that 
was unsuspected preoperatively and those who 
had not had such complication is illustrated in 
Figure S. Recurrence of the tumor was the cause 
of death in four of the five deaths that occurred 
among the patients with cholangiocarcinoma. Sta-
tistically, unsuspected cholangiocarcinoma was as-
sociated with a significant (chi-square equals 5.0; 
p=0.(26) reduction in the actual survival rate 
after transplantation, even after adjustment for 
the risk scores (chi-square equals 3.7; p=0.OS4). 
Meanwhile, the cumulative survival rate measured 
by the Kaplan-Meier method was similar (chi-
square equals 2.7; p=0.103) to that predicted by 
the Mayo model (Fig. 6). 
There was evidence of an improvement in out-
come over time. The 32 recipients of OHTx who 
received FK-S06 after March 1989 had better one 
year actual survival rates (0.97 ± 0.(3) compared 
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FIG. R. Scatter plots for the Mayo model risk score values 
of the patients with primary sclerosing cholangitis who re-
ceived transplantation each year among the three immu-
nosuppressive groups. 
with the 184 patients who were treated with cy-
closporin (0.84±0.03) since December 1981. In 
the group receiving cyclosporin, the 159 patients 
who underwent transplantation after the intro-
duction of OKT3 (November 1984) also had better 
one year Kaplan-Meier survival rates (0.86 ± 0.03) 
compared with the 25 patients who received 
OHTx before that time (0.72 ± 0.09). The dif-
ference in the overall survival rate between the 
three groups was not significant (chi-square 
equals 4.9; p=0.086) (Fig. 7). Because there was 
no evidence of a change in the level of the risk 
score for the patients receiving transplantation 
since 1981 (Fig. 8), this improvement most likely 
reflects the use of more effective immunosup-
pressive agents in addition to the improved medi-
cal technologic factors and increased surgical, 
as well as clinical, experience. 
At the last follow-up evaluation, the functional 
status of each patient was assessed according to 
the classification system of the United Network 
for Organ Sharing. Information on functional 
status was available for all of the 169 patients 
with PSC receiving OHTx who were alive at that 
date. Of these, 145 were working full time, 20 
were working part time, three were homebound 
and unable to work and one patient was hospi-
talized. 
DISCUSSION 
Different mathematical models have been made 
and proven useful in predicting survival of con-
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servatively treated patients with different types 
of hepatic diseases (22-27). In patients with PSC, 
these models have used univariate (28-33) and 
multivariate (4, 34, 35) approaches. The Cox re-
gression analysis has proved to be a useful sta-
tistical method for identifying variables that have 
independent prognostic significance. 
The multivariate technique to predict survival 
among patients with PSC was first used in 1987 
(34). Such an attempt was followed by two other 
independent trials conducted at Mayo Clinic and 
King's College using a similar statistical approach 
(4, 3F)). In these two models, a risk score could 
be calculated and translated into a survival curve 
to estimate survival for the individual patient. 
Although the results of both studies provide some 
objective evidence with regard to disease severity 
and estimation of survival, neither one was cross-
validated and the general application to the PSC 
patients remained unknown. 
Recently, others (5) were able to refine and 
cross-validate the Mayo model by applying the 
Cox regression procedure to a geographically het-
erogenous population, which included an expanded 
pool of patients with PSC that were referred to 
five international medical centers, including King's 
College. It is a four variable model that includes 
age, total serum bilirubin level, presence or ab-
sence of splenomegaly and hepatic histologic stage. 
In addition to age, the histologic stage seems 
to be a common survival predictor in most studies 
(4, 5, 35). However, the invasive nature of the 
percutaneous needle biopsy of the liver with the 
possibility of sampling errors seems to be a lim-
iting factor to the beneficial use of histologic 
stage for repeated and accurate estimation of 
predicted patient survival. The levels of serum 
bilirubin in these patients reflect not only the 
degree of parenchymal damage to the liver, but 
also the extent and type of biliary sclerosis char-
acteristic ofPSC. The development of biliary sludge 
and the occurrence of intermittent bacterial cho-
langitis can have a significant transient influence 
on serum bilirubin levels, which should be con-
sidered in each patient to avoid underestimation 
of the predicted survival. The enlargement of 
the spleen indicates the occurrence of significant 
portal hypertension. 
Using the simulated control technique as es-
timated by the PSC Mayo model, the results of 
this study showed a statistically significant im-
provement in overall survival rate of patients with 
PSC after transplantation, despite the initial mor-
tality related to operation and events in the pe-
rioperative period. The improvement survival rate 
at five years was greatest for the high and mod-
erate risk groups, with a difference between actual 
and average predicted survival rate of 74 and 
42 percent, respectively. Even in the lowest risk 
group, that is, those who had tl1e best prognosis 
according to the model for survival with no treat-
ment, there was a significant improvement in 
survival rate at five years of 18 percent. Such 
beneficial effect of OHTx has been previously 
documented in other non controlled studies (1-
3). 
The similarity between actual survival and Mayo 
model estimates of survival during the first three 
months after transplantation suggests that the pe-
rioperative mortality was related to the pretrans-
plantation status of each patient, which was as-
sessed by the Mayo model. This is statistically 
confirmed by the significant relationship between 
the Mayo model risk score and the three months' 
actual survival rate after transplantation. The cross-
ing of the actual "Kaplan-Meier" survival curves 
for the three risk groups during the late post-
operative course (Fig. 2) suggests that the relation 
between pre transplantation risk and post-trans-
plantation survival is not long term. 
There are some important limitations to ap-
plying the Mayo model to transplant recipients 
with PSC. First, the patients who received OHTx 
at Pittsburgh and Mayo Medical centers were at 
a substantially higher risk than the 392 patients 
of whom the Mayo model was constructed. Such 
high values of the individual risk factors and 
calculated risk score probably reflect the later 
stage of the illness of the patient receiving trans-
plantation. Because the precision of the model 
decreases for patients at higher risk of dying 
(5), the model may be less reliable in such high-
risk patients, making it difficult to assess the im-
provement in the survival after transplantation. 
A second limitation concerns the risk of cho-
langiocarcinoma among patients with PSC (36-
40). The actual survival of the patients who had 
undergone transplantation and were found to 
have cholangiocarcinoma in the excised liver was 
similar to the estimated survival predicted by the 
Mayo model. The failure to achieve significant 
improvement in survival among these patients 
may be the result of the limited benefit of hepatic 
replacement in these patients or the overestima-
tion of their predicted survival, or both, because 
the calculated risk score for the Mayo model 
did not and could not include a component for 
such undiagnosed "incidental" cholangiocarci-
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noma. As the diagnostic ability to detect early 
cholangiocarcinoma is improved, this refinement 
may influence decisions for OHTx in such pa-
tients. 
A third limitation is the existence of other 
risk factors that are not reflected in the Mayo 
model risk score and could influence actual and 
predicted survival rates. Although not statistically 
significant, a history of inflammatory intestinal 
disease and pretransplant biliary or portal hy-
pertensive, or both, surgical treatment was asso-
ciated with a less favorable actual survival rate 
after transplantation. Accordingly, the current 
Mayo model could overestimate the predicted 
survival rate of these patients. However, the Mayo 
model predicted survival rates in patients who 
had previous biliary drainage could be underes-
timated because of the expected reduction in se-
rum bilirubin level after such palliative treatment. 
However, the current group of patients who had 
a history of surgical, endoscopic or roentgenologic, 
or both, drainage of the biliary tract showed higher 
(p=O.OOI) serum bilirubin levels at the time of 
transplantation (16.6 ± 13.7 milligrams per deci-
liter) compared with those who did not receive 
such therapy (1l.6 ± 12.4 milligrams per decili-
ter) . 
A final limitation is that bias would have been 
introduced into this evaluation of the effect of 
transplantation if the patients receiving transplan-
tation uniformly had had a worse or a better 
prognosis than the patients in the Mayo model, 
even after adjustment for differences in severity 
of disease as measured by the risk score. Because 
the disease was at a more advanced stage in the 
patients receiving transplantation, the prognosis 
could have remained worse after adjustment for 
risk, leading to an underestimate of the benefit 
of transplantation. However, they could have been 
in better condition than the patients in the Mayo 
model after adjustment for risk, because of the 
careful screening performed when the patients 
were selected for an extensive surgical procedure. 
This would have led to an overestimation of the 
transplantation benefIt. In our judgment, if bias 
did exist, the net tendency was toward under-
estimating the true benefit of transplantation. 
SUMMARY 
OHTx substantially improves the long term sur-
vival rate in patients with PSC who are at a wide 
variety of risk levels as measured by the Mayo 
model. The results reported herein may under-
estimate the improvement in survival to be ex-
pected in the future because post-transplantation 
survival rates have improved with advanced medi-
cal technologic factors, greater surgical experi-
ence, better postoperative care and new more 
effective immunosuppressive agents, such as OKT3 
and FK-506. Of the patients who survive trans-
plantation, 98 percent return to work at least 
part time. 
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